BNTX - Veru: On Right Track For FDA EUA Submission
- An Emergency Use Authorization submission of sabizabulin for high-risk hospitalized Covid-19 patients is expected Q2 of 2022.
- With EUA and then possibly NDA occurring for sabizabulin, Veru would be in a good position to develop advance purchase orders with several Government agencies around the world.
- Sabizabulin is also being explored for prostate cancer and breast cancer in the pipeline; Enobosarm is another drug being developed for breast cancer.
- Veru had $112 million in cash as of March 31, 2022; enough to fund its operations for at least the next 12 months.
For further details see:
Veru: On Right Track For FDA EUA Submission